Other Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2026

Balance Sheet Related Disclosures [Abstract]

Summary of Components of Property and Equipment, Net

Property and equipment, net balances consisted of the following:


(in thousands)		June 30, 2026				December 31, 2025
Research equipment		$	14,291			$	14,942
Computers and software			948				1,069
Office equipment and furniture			402				604
Leasehold improvements			2,600				2,612
Total			18,241				19,227
Less accumulated depreciation and amortization			(12,878	)			(12,491	)
Property and equipment, net		$	5,363			$	6,736

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following:


(in thousands)		June 30, 2026				December 31, 2025
Accrued compensation		$	7,763			$	6,948
Cystic Fibrosis Foundation liability			5,882				6,394
Current portion of operating lease liabilities			3,967				4,214
Accrued facilities costs			840				1,400
Clinical trial accruals			851				399
Legal accrual			131				771
Other accrued research and development expenses			3,412				3,772
Total		$	22,846			$	23,898

Schedule of Cash and Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows:


(in thousands)		June 30, 2026				June 30, 2025
Cash and cash equivalents		$	191,483			$	196,467
Restricted cash			—				55,000
Non-current restricted cash			2,028				1,885
Total cash, cash equivalents and restricted cash		$	193,511			$	253,352